Emmaus Seeks Approval of Oral Medication Endari in Kuwait

Emmaus Seeks Approval of Oral Medication Endari in Kuwait

300008

Emmaus Seeks Approval of Oral Medication Endari in Kuwait

Emmaus Life Sciences has submitted an application seeking the approval of its oral medication Endari (L-glutamine) to treat sickle cell disease (SCD) in Kuwait. The company announced that the Kuwait Drug and Food Control administration, which is responsible for registering pharmaceutical products in the country, has accepted its request for fast-track review of Endari. A decision from the regulatory authority is expected within one year. “We are pleased to announce the submission of our marketing…

You must be logged in to read/download the full post.